Phase II trial of mitoxantrone in refractory acute leukemia.
Mitoxantrone was administered to 41 adults with refractory acute leukemia. The initial dose employed was 4 mg/m2/day X 5 days. Eventually a starting dose of 10 mg/m2/day X 5 days was used, with some patients receiving a subsequent course at 12 mg/m2/day X 5 days. Three patients had a complete response, one a partial response, and one hematologic improvement. Although antileukemia effect was more frequent at the higher doses, so was death following treatment.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone
D000880:Anthraquinones; D000970:Antineoplastic Agents; D008942:Mitoxantrone